NovoCure Limited
Every calculator, already run for NVCR
Open the full toolkit →You have the numbers on NVCR. Get the argument.
A written report on which of these readings actually decide the outcome for NovoCure Limited, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering NVCRAnalyst Price Target Disagreement for NovoCure Limited
Wall Street's bull case implies +190% from the current price; the bear case implies -5%. A 195% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NVCR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR — frequently asked
Is NVCR a buy right now?
Wall Street's consensus rating on NovoCure Limited is Buy across 7 analysts, with a mean price target of $27.14 (+51% vs. the current $17.94). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is NVCR overvalued?
NVCR trades at — trailing earnings, against a DCF fair value of $4 per share. The current price implies 26% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is NVCR's next earnings date?
NovoCure Limited is next scheduled to report earnings around Oct 29, 2026. A full NVCR research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for NovoCure Limited?
Analysts covering NovoCure Limited (NVCR) range from a bear-case target of $17.00 to a bull-case high of $52.00, with a mean consensus target of $27.14 across 7 analysts. The spread of $35.00 (195% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare NovoCure Limited against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For NovoCure Limited
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NVCR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on NovoCure Limited, in minutes. 3 free reports included with every account — no credit card required.